Home
Live Updates
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations : comparemela.com
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...
Related Keywords
Brussels ,
Bruxelles Capitale ,
Belgium ,
Smyrna ,
Izmir ,
Turkey ,
Erica Puntel ,
Antje Witte ,
Hidradenitis Suppurativa ,
Emmanuel Caeymaex ,
Group Of Companies ,
Drug Administration ,
Ucb Inc ,
Twitter ,
Immunology Solutions ,
Us Communications ,
Biologics License Application ,
Executive Vice President ,
Important Safety Information ,
United States ,
Herpes Simplex Infections ,
Euronext Brussels ,
Oral Presentation ,
Rev Dis ,
Clin Cosmet Investig ,
Its Effect ,
Study Participants With Moderate ,
Severe Hidradenitis Suppurativa ,
Ucb ,
comparemela.com © 2020. All Rights Reserved.